TY - JOUR
T1 - Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases
T2 - an in vitro study using cell lines.
AU - Sampson, Heidi M.
AU - Lam, Hung
AU - Chen, Pei Chun
AU - Zhang, Donglei
AU - Mottillo, Cristina
AU - Mirza, Myriam
AU - Qasim, Karim
AU - Shrier, Alvin
AU - Shyng, Show Ling
AU - Hanrahan, John W.
AU - Thomas, David Y.
N1 - Funding Information:
We thank Dr. Robert J. Bridges (Rosalind Franklin University of Medicine and Science, Chicago) and the CFFT Inc., for providing VRT-325 and Dr. Eckhard Ficker (Case Western Reserve University, Cleveland) for providing the stable HEK293 HERG G601S cell line. We thank Dr. Peter Deen (NCMLS, The Netherlands) and Dr. Torsten Schöneberg (University of Leipzig, Germany) for providing V2R V206D and V2R L292P plasmids, respectively. This work was funded by grants from Cystic Fibrosis Canada, Cystic Fibrosis Foundation Therapeutics, Inc., the Canadian Institutes of Health Research (to DYT, J.W.H. and AS), NIH R01 DK05699 and a grant from the March of Dimes Research Foundation (to S-LS).
PY - 2013
Y1 - 2013
N2 - Many genetic diseases are due to defects in protein trafficking where the mutant protein is recognized by the quality control systems, retained in the endoplasmic reticulum (ER), and degraded by the proteasome. In many cases, the mutant protein retains function if it can be trafficked to its proper cellular location. We have identified structurally diverse correctors that restore the trafficking and function of the most common mutation causing cystic fibrosis, F508del-CFTR. Most of these correctors do not act directly as ligands of CFTR, but indirectly on other pathways to promote folding and correction. We hypothesize that these proteostasis regulators may also correct other protein trafficking diseases. To test our hypothesis, we used stable cell lines or transient transfection to express 2 well-studied trafficking disease mutations in each of 3 different proteins: the arginine-vasopressin receptor 2 (AVPR2, also known as V2R), the human ether-a-go-go-related gene (KCNH2, also known as hERG), and finally the sulfonylurea receptor 1 (ABCC8, also known as SUR1). We treated cells expressing these mutant proteins with 9 structurally diverse F508del-CFTR correctors that function through different cellular mechanisms and assessed whether correction occurred via immunoblotting and functional assays. Results were deemed significantly different from controls by a one-way ANOVA (p < 0.05). Here we show that F508del-CFTR correctors RDR1, KM60 and KM57 also correct some mutant alleles of other protein trafficking diseases. We also show that one corrector, the cardiac glycoside ouabain, was found to alter the glycosylation of all mutant alleles tested. Correctors of F508del-CFTR trafficking might have broader applications to other protein trafficking diseases.
AB - Many genetic diseases are due to defects in protein trafficking where the mutant protein is recognized by the quality control systems, retained in the endoplasmic reticulum (ER), and degraded by the proteasome. In many cases, the mutant protein retains function if it can be trafficked to its proper cellular location. We have identified structurally diverse correctors that restore the trafficking and function of the most common mutation causing cystic fibrosis, F508del-CFTR. Most of these correctors do not act directly as ligands of CFTR, but indirectly on other pathways to promote folding and correction. We hypothesize that these proteostasis regulators may also correct other protein trafficking diseases. To test our hypothesis, we used stable cell lines or transient transfection to express 2 well-studied trafficking disease mutations in each of 3 different proteins: the arginine-vasopressin receptor 2 (AVPR2, also known as V2R), the human ether-a-go-go-related gene (KCNH2, also known as hERG), and finally the sulfonylurea receptor 1 (ABCC8, also known as SUR1). We treated cells expressing these mutant proteins with 9 structurally diverse F508del-CFTR correctors that function through different cellular mechanisms and assessed whether correction occurred via immunoblotting and functional assays. Results were deemed significantly different from controls by a one-way ANOVA (p < 0.05). Here we show that F508del-CFTR correctors RDR1, KM60 and KM57 also correct some mutant alleles of other protein trafficking diseases. We also show that one corrector, the cardiac glycoside ouabain, was found to alter the glycosylation of all mutant alleles tested. Correctors of F508del-CFTR trafficking might have broader applications to other protein trafficking diseases.
UR - http://www.scopus.com/inward/record.url?scp=84872122357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872122357&partnerID=8YFLogxK
U2 - 10.1186/1750-1172-8-11
DO - 10.1186/1750-1172-8-11
M3 - Article
C2 - 23316740
AN - SCOPUS:84872122357
SN - 0973-3698
VL - 8
JO - Indian Journal of Rheumatology
JF - Indian Journal of Rheumatology
ER -